# Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of Droxidopa

> **NCT01149629** · PHASE1 · COMPLETED · sponsor: **Chelsea Therapeutics** · enrollment: 24 (estimated)

## Conditions studied

- Symptomatic Neurogenic Orthostatic Hypotension

## Interventions

- **DRUG:** Droxidopa
- **DRUG:** Droxidopa
- **DRUG:** Droxidopa

## Key facts

- **NCT ID:** NCT01149629
- **Lead sponsor:** Chelsea Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2013-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01149629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01149629, "Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of Droxidopa". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01149629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*